FDA Commissioner Dr. Marty Makary is set to step down after a tumultuous 13-month tenure, leaving behind a legacy of controversy and upheaval at the nation's top food and drug regulatory agency. During his time at the helm, the FDA faced intense scrutiny over its handling of key issues, including the approval process for new medications and the agency's response to emerging public health threats. Makary's departure comes as the agency grapples with challenges from both within and outside, including bipartisan criticism of its regulatory approach and growing pressure from lawmakers to reform the FDA's operations. As the search for a new commissioner begins, questions remain about what the future holds for the FDA and how the agency will navigate the complex landscape of food and drug safety.
The resignation would end Dr. Marty Makary's 13-month stint running the Food and Drug Administration, a period marked by turmoil and controversy.
